bio-manufacturing
GLOBAL INNOVATION CONGRESS
20th & 21st October 2026
Boston Massachusetts USA
bio-manufacturing
GLOBAL INNOVATION
CONGRESS 2026
20-21 OCTOBER BOSTON USA
OVERCOMING LIMITATIONS IN
BIOMANUFACTURING BIOPROCESSING
AI, DIGITALIZATION 4.0
SUPPLY CHAIN,
CELL AND GENE THERAPY
Armon Sharel Ph.D
Founder & CEO
Portal Biotech
Lada Laenen Sc.D
SVP, Global Head
of Manufacturing Sciences
and Technology
GSK
Alain Bernard
VP Techical
Operations
UCB
Tom Spitznagel
SVP BioPharmaceutical
Development
Macrogenics
Biological Manufacturing - Integrated Holistic Approach
Proudly presenting the highly anticipated and exciting Bio-manufacturing 2026 Annual program; Comprised of fully renowned world class speaker and industry thought leaders. Following a comprehensive research process undertaken with an expert panel of advisory board and results from delegates surveys. The program is rich with robust content on innovation and pivotal breakthroughs; giving you insight on the latest industry trends and technologies impacting growth in the Biologics market.
As Biological products are moving from niche to mainstream, the industry is facing a paradigm shift in cost, quality, complexity, and scale, creating opportunities to develop new and different technologies and operating models. Achieving the next phase of the industry potential will require a further revolution, not only in the laboratory but also in strategy, technology, and operations. Decisions made today will affect companies' competitive positions years or even decades into the future.
Access the unparalleled wisdom of inside knowledge from leading companies such as Pfizer and GSK. Industry peers give presentations and case studies on success in overcoming key challenges and bottlenecks. Engage interactively with globally renowned leaders in round table group sessions and panel discussion. Key Topics of significants gains from deployment of technological innovation and techniques.
.png)
.jpg)
.jpeg)
A compiling program that reflects key strategic issues that senior executives have identified
​
Intelligence that flourishes within biological process communities
​
-
4.0 BioProcessing Technology
-
AI Integration
-
Digital Twin
-
Smart Facilities
-
Qbd, PAT, MES, Analytics
.png)
AI, Digitalization, Automation
.png)
Fundamental evolution to meet quality and compliance challenges: Implementation of next generation digital Bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up.
Single-use systems key technologies and considerations: Designing an integrated fluid handling systems. Improve efficiency and cost through flexible, knowledge based approaches. digital bioprocessing 4.0 technology, integrating automation processing and systems.
​
Facilities upgrades 4.0: Overcoming challenges with aging plants moving towards flexible manufacturing, automated processing and systems implementation.
​
Facility design for continuous flexible multi-product biomanufacturing at scale: Scaling down to decide which new technologies are relevant and which can be best applied as process intensification.
Process Development and Manufacturing evolution: Advances in Process Development and Manufacturing shaping the Future of Cell and Gene Therapy development.
Manufacturing Technology
& Strategy
Revolutionizing Gene-Modified Cell Therapies: Leveraging advanced analytics and Agentic AI for Scalable Quality to transform the vein-to-vein process, achieving unprecedented levels of efficiency, cost-effectiveness, and
Reducing time to market strategies: Strategies to speed up the development process of CGTs, ensuring that therapies reach patients faster while maintaining high standards of safety and efficacy.
Bridging the characterisation & analytics gap in CGT: Best practices and emerging solutions. Collaborative approaches to tackling technical challenges
Beyond AAV- Non-Viral and Novel Delivery Systems: The Future of In Vivo Delivery Systems: LNP and alternatives (EVs, VLPs etc) and machine learning-powered targeting.
How ready is the industry for the tidal wave of biopharma demand: Navigating the Unique Manufacturing and Supply Chain Challenges in Commercializing Cell and Gene Therapy
Staying Ahead of the Curve in an Increasingly Complex Regulatory World: Establishing a quality mindset across manufacturing and operations Examining the cost of compliance and striking a careful balance between quality and cost management
Revolutionizing Gene-Modified Cell Therapies: Leveraging advanced analytics and Agentic AI for Scalable Quality to transform the vein-to-vein process, achieving unprecedented levels of efficiency, cost-effectiveness, and
Reducing time to market strategies: Strategies to speed up the development process of CGTs, ensuring that therapies reach patients faster while maintaining high standards of safety and efficacy.
Bridging the characterisation & analytics gap in CGT: Best practices and emerging solutions. Collaborative approaches to tackling technical challenges
Beyond AAV- Non-Viral and Novel Delivery Systems: The Future of In Vivo Delivery Systems: LNP and alternatives (EVs, VLPs etc) and machine learning-powered targeting.
How ready is the industry for the tidal wave of biopharma demand: Navigating the Unique Manufacturing and Supply Chain Challenges in Commercializing Cell and Gene Therapy
Staying Ahead of the Curve in an Increasingly Complex Regulatory World: Establishing a quality mindset across manufacturing and operations Examining the cost of compliance and striking a careful balance between quality and cost management
Cell and Gene Therapies
Upstream revolution: Beyond incremental improvements, breakthroughs in redefining what's biologically possible.
The Future of Upstream Automation: AI-powered continuous processing platforms reduces optimization timelines and volumetric productivity challenges.
Cell Line Engineering: Automated CHO Cell lines and Expression System for enhanced improved productivity. Accelerate Timelines by Integrating Cell Line Development and Manufacturing Programs.
Optimization of fermentation/cell culture media: Explore next generation Technology, strategies and Innovation that improves Cell Culture Process Development to increase yield, reduce wastage and consistently produce high quality biological end product.
Innovative monitoring, detection, measurement, control technology: Process analysis, optimisation and automation, improving efficiency and productivity at advancing critical stages. Identify optimal time-point of feeding, filtration and harvest.
Upstream Processing
-
Downstream Process Development: Global Strategy to Enrich Full Capsids in Adeno-associated Viral Vector Based Gene Therapy.
-
New developments in chromatography: How will this shape the future of protein purification? Bridging the gap between the structure of purified proteins and their function in a cellular context.
-
The future of downstream processing: Overcoming current challenges in developing Purification Platforms to alleviate Bottlenecks.
-
Advances in Recovery and purification: Leveraging technology innovation to overcome the direct impact of high titer processes In downstream processing.
​
-
New virus and pathogen clearance and safety in biologics: ​ Achieving greater assurance on viral clearance for more complicated products. Risk Assessment and management, design, Evaluation, and Characterisation of Procedures.
Recovery & Purification
AI, Digitalization, Automation
-
4.0 BioProcessing Technology
-
AI Integration
-
Digital Twin
-
Smart Facilities
-
Qbd, PAT, MES, Analytics
bio-manufacturing
GLOBAL INNOVATION CONGRESS
20th & 21st October 2026
Boston Massachusetts US
Fundamental evolution to meet quality and compliance challenges: Implementation of next generation digital Bioprocessing 4.0 and integrating automation technology for Increased GMP compliance and consistency. Enabling acceleration of processing research and scale-up.
Single-use systems key technologies and considerations: Designing an integrated fluid handling systems. Improve efficiency and cost through flexible, knowledge based approaches. digital bioprocessing 4.0 technology, integrating automation processing and systems.
​
Facilities upgrades 4.0: Overcoming challenges with aging plants moving towards flexible manufacturing, automated processing and systems implementation.
​
Facility design for continuous flexible multi-product biomanufacturing at scale: Scaling down to decide which new technologies are relevant and which can be best applied as process intensification.
Process Development and Manufacturing evolution: Advances in Process Development and Manufacturing shaping the Future of Cell and Gene Therapy development.
Manufacturing Technology
& Strategy
Upstream Processing
Upstream revolution: Beyond incremental improvements, breakthroughs in redefining what's biologically possible.
The Future of Upstream Automation: AI-powered continuous processing platforms reduces optimization timelines and volumetric productivity challenges.
Cell Line Engineering: Automated CHO Cell lines and Expression System for enhanced improved productivity. Accelerate Timelines by Integrating Cell Line Development and Manufacturing Programs.
Optimization of fermentation/cell culture media: Explore next generation Technology, strategies and Innovation that improves Cell Culture Process Development to increase yield, reduce wastage and consistently produce high quality biological end product.
Innovative monitoring, detection, measurement, control technology: Process analysis, optimisation and automation, improving efficiency and productivity at advancing critical stages. Identify optimal time-point of feeding, filtration and harvest.
Revolutionizing Gene-Modified Cell Therapies: Leveraging advanced analytics and Agentic AI for Scalable Quality to transform the vein-to-vein process, achieving unprecedented levels of efficiency, cost-effectiveness, and
Reducing time to market strategies: Strategies to speed up the development process of CGTs, ensuring that therapies reach patients faster while maintaining high standards of safety and efficacy.
Bridging the characterisation & analytics gap in CGT: Best practices and emerging solutions. Collaborative approaches to tackling technical challenges
Beyond AAV- Non-Viral and Novel Delivery Systems: The Future of In Vivo Delivery Systems: LNP and alternatives (EVs, VLPs etc) and machine learning-powered targeting.
How ready is the industry for the tidal wave of biopharma demand: Navigating the Unique Manufacturing and Supply Chain Challenges in Commercializing Cell and Gene Therapy
Staying Ahead of the Curve in an Increasingly Complex Regulatory World: Establishing a quality mindset across manufacturing and operations Examining the cost of compliance and striking a careful balance between quality and cost management
Cell And Gene Therapy
​
-
Downstream Process Development: Global Strategy to Enrich Full Capsids in Adeno-associated Viral Vector Based Gene Therapy.
-
New developments in chromatography: How will this shape the future of protein purification? Bridging the gap between the structure of purified proteins and their function in a cellular context.
-
The future of downstream processing: Overcoming current challenges in developing Purification Platforms to alleviate Bottlenecks.
-
Advances in Recovery and purification: Leveraging technology innovation to overcome the direct impact of high titer processes In downstream processing.
​
-
New virus and pathogen clearance and safety in biologics: ​ Achieving greater assurance on viral clearance for more complicated products. Risk Assessment and management, design, Evaluation, and Characterisation of Procedures.
Recovery & Purification